Hypertonic Saline 75% vs Mannitol 20%

Brain Tumor Clinical Trial

Official title:

Comparison of Equiosmolar Doses of Mannitol 20% Versus Hypertonic Saline 7.5% Infusion in the Reduction of Brain Bulk During Elective Craniotomies for Supratentorial Brain Tumor Resection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00199511
• Other study ID #: R-05-154
• Status: Completed
• Phase: N/A
• Start date: January 2005
• Est. completion date: April 2007

Study information

• Verified date: November 2018
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of Hypertonic Saline 7.5% vs Mannitol 20% on brain bulk (using a 4 point scale), intracranial pressure (subdural catheter)and the changes on serum and urinary Na, K and Osmolarity during elective craniotomy for brain tumor resection.

Description:

Raised intracranial pressure occurs following an expansion of an intracranial mass e.g. hematoma or brain tumor and if left untreated, can lead to brain ischemia, stroke and death.

Strategies for reducing raised intracranial pressure include hyperventilation, use of a hyperosmolar agent and the evacuation of the intracranial mass.

The two hypertonic solutions most commonly used are Mannitol 20% and Hypertonic Saline 7.5%.

During elective neurosurgical removal of a brain tumour, the anesthesiologist needs to reduce intracranial pressure and provide good operating brain conditions to avoid brain ischemia.

Currently, Mannitol 20% is routinely used intra-operatively in these patients to reduce brain bulk and intracranial pressure and to improve brain operating conditions.

However, Mannitol itself can cause secondary effects that can be deleterious to the neurological patient. Mannitol causes a diuresis which may lead to systemic hypovolemia and hypotension, and adverse changes in serum and urinary sodium, potassium and osmolarity.

Experience with Hypertonic saline 7.5%, has been mainly in brain injured patients either in the Emergency Dept or in the Intensive care setting. There is growing evidence that Hypertonic saline 7.5% is just as effective as Mannitol 20% in reducing raised intracranial pressure, especially in traumatic brain injury and it has become a widely accepted form of treatment. One of the advantages of Hypertonic saline is that it does not cause a diuresis and therefore less likely to cause hypotension and hypovolemia. While transient hypernatremia has been observed after the administration of hypertonic saline, there have been no clinical consequences.

Unfortunately there have been only two studies which compared the effectiveness of Hypertonic saline and Mannitol during elective brain surgery. One of them, Gemma et al, failed to demonstrate any difference in the reduction of brain bulk between Mannitol and Hypertonic saline. However the 2 solutions used had different osmolarities and this may have had a confounding effect on the results. In the other study (published in Polish), the authors found a 20% reduction in brain bulk in favour of hypertonic saline. In view of these two opposing findings, we feel that another investigation is warranted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 162
• Est. completion date: April 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• ASA physical status I - 3.

• Age >18 years.

• Scheduled for elective craniotomies for supratentorial brain tumour resection.

• Written informed consent.

Exclusion Criteria:

• Within the past six months, a history of unstable angina pectoris and/or having a myocardial infarction.

• Electrocardiogram abnormalities indicating severe ischemia.

• Congestive heart failure.

• Glasgow coma sore < 9

• Refusal to participate or refusal to agree to randomization.

• Known renal failure

• Known poorly controlled diabetes.

Related Conditions & MeSH terms

• Brain Neoplasm
• Brain Neoplasms
• Brain Tumor
• Neoplasm, Supratentorial
• Neoplasms
• Supratentorial Neoplasms
• Tumor, Brain
• Tumor, Supratentorial

Intervention

Drug:
• Administration of Hypertonic Solution 7.5% vs Mannitol 20%

Locations

Country	Name	City	State
Canada	University Hospital LHSC	London	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgeon's assessment of brain bulk.
Primary	ICP reduction
Secondary	Changes in intracranial pressure
Secondary	Changes in serum and urine levels of sodium, potassium and osmolarity.